UNLABELLED: Schimke immuno-osseous dysplasia (SIOD) is a rare autosomal recessive spondylo-epiphyseal dysplasia. The characteristic features of SIOD include 1) short stature with hyperpigmented macules and an unusual facies, 2) proteinuria with progressive renal failure, 3) lymphopenia with recurrent infections, and 4) cerebral ischaemia. Although 25 patients have been reported with this disorder, the clinical course and phenotype of SIOD are not well characterized. This report summarizes the clinical findings, course and treatment of reported patients and includes 14 additional patients with SIOD. We emphasize the high incidence of cerebral ischaemia and ocular abnormalities, define the high incidence of thyroid dysfunction and blood cytopenia, and confirm the absence of effective and durable medical therapies. CONCLUSION: Schimke immuno-osseous dysplasia is a multi-system autosomal recessive disorder with variable expression that affects the skeletal, renal, immune, vascular, and haematopoietic systems. Medical therapy is limited especially for more severely affected individuals.
UNLABELLED: Schimke immuno-osseous dysplasia (SIOD) is a rare autosomal recessive spondylo-epiphyseal dysplasia. The characteristic features of SIOD include 1) short stature with hyperpigmented macules and an unusual facies, 2) proteinuria with progressive renal failure, 3) lymphopenia with recurrent infections, and 4) cerebral ischaemia. Although 25 patients have been reported with this disorder, the clinical course and phenotype of SIOD are not well characterized. This report summarizes the clinical findings, course and treatment of reported patients and includes 14 additional patients with SIOD. We emphasize the high incidence of cerebral ischaemia and ocular abnormalities, define the high incidence of thyroid dysfunction and blood cytopenia, and confirm the absence of effective and durable medical therapies. CONCLUSION:Schimke immuno-osseous dysplasia is a multi-system autosomal recessive disorder with variable expression that affects the skeletal, renal, immune, vascular, and haematopoietic systems. Medical therapy is limited especially for more severely affected individuals.
Authors: Rémy Bétous; Aaron C Mason; Robert P Rambo; Carol E Bansbach; Akosua Badu-Nkansah; Bianca M Sirbu; Brandt F Eichman; David Cortez Journal: Genes Dev Date: 2012-01-15 Impact factor: 11.361
Authors: Alireza Baradaran-Heravi; Kyoung Sang Cho; Bas Tolhuis; Mrinmoy Sanyal; Olena Morozova; Marie Morimoto; Leah I Elizondo; Darren Bridgewater; Joanna Lubieniecka; Kimberly Beirnes; Clara Myung; Danny Leung; Hok Khim Fam; Kunho Choi; Yan Huang; Kira Y Dionis; Jonathan Zonana; Kory Keller; Peter Stenzel; Christy Mayfield; Thomas Lücke; Arend Bokenkamp; Marco A Marra; Maarten van Lohuizen; David B Lewis; Chad Shaw; Cornelius F Boerkoel Journal: Hum Mol Genet Date: 2012-02-28 Impact factor: 6.150
Authors: Osama Safdar; Sherif M El-Desoky; Detlef Bockenhauer; Neil Sebire; Neil Sabire; Jameela A Kari Journal: Pediatr Nephrol Date: 2014-01-29 Impact factor: 3.714
Authors: Kshamta B Hunter; Thomas Lücke; Jürgen Spranger; Sarah F Smithson; Harika Alpay; Jean-Luc André; Yumi Asakura; Radovan Bogdanovic; Dominique Bonneau; Robyn Cairns; Karlien Cransberg; Stefan Fründ; Helen Fryssira; David Goodman; Knut Helmke; Barbara Hinkelmann; Guiliana Lama; Petra Lamfers; Chantal Loirat; Silvia Majore; Christy Mayfield; Bertram F Pontz; Cristina Rusu; Jorge M Saraiva; Beate Schmidt; Lawrence Shoemaker; Sabine Sigaudy; Natasa Stajic; Doris Taha; Cornelius F Boerkoel Journal: Eur J Pediatr Date: 2009-12-15 Impact factor: 3.183